What is Alamar Biosciences 's SG&A?

Alamar Biosciences (ALMR) reported SG&A of $13.79M in Q1 2026.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Alamar Biosciences ALMR SG&A

SG&A at other companies

Vertex PharmaceuticalsVRTX

$493.7M+24.5%

Teledyne TechnologiesTDY

$237.4M+1.5%

CortevaCTVA

$725M+8.0%

CumminsCMI

$845M+9.6%

MedtronicMDT

$3.06B+12.4%

GartnerIT

$726.35M-0.5%

Other financials

Income statement

See full

Revenue$26.0M+98.9%

Gross profit$14.5M+126%

Operating income-$12.3M-44.4%

Net income-$21.3M-178%

EPS (diluted)-$1.74-156%

Balance sheet

See full

Cash & equivalents$64.6M—

Total debt$30.6M—

Total equity-$178.1M—

Total assets$186.5M—

Cash flow

See full

Operating cash flow-$20.3M-55.7%

CapEx$600.0K+8.3%

Free cash flow-$20.9M-53.8%

Valuation

See full

Market cap$1.52B—

Enterprise value$1.49B—

Returns & leverage

See full

Debt / equity-0.2×—

Current ratio5.9×—

Where this comes from

Reported directly by Alamar Biosciences in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Alamar Biosciences ’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alamar Biosciences 's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Alamar Biosciences 's SG&A?: Alamar Biosciences (ALMR) reported SG&A of $13.79M in Q1 2026.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.